Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes

Diabetes

Volumn 65, Issue 5, 2016, Pages 1190-1196

  Ferrannini, Ele ^a,b   Baldi, Simona ^b   Frascerra, Silvia ^b   Astiarraga, Brenno ^b   Heise, Tim ^c   Bizzotto, Roberto ^d   Mari, Andrea ^d   Pieber, Thomas R ^e   Muscelli, Elza ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Profil   (Germany)

^d CNR   (Italy)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CARBOHYDRATE; EMPAGLIFLOZIN; FUEL; GLUCAGON; GLYCEROL; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2; TRIACYLGLYCEROL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; C REACTIVE PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

ARTICLE; CALORIMETRY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FATTY ACID METABOLISM; GLUCONEOGENESIS; GLUCOSURIA; HUMAN; KETOGENESIS; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOLYSIS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINALYSIS; AGONISTS; ALGORITHM; ANTAGONISTS AND INHIBITORS; BLOOD; CARBOHYDRATE METABOLISM; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENERGY METABOLISM; GLUCOSE INTOLERANCE; LIPID METABOLISM; METABOLISM; MULTICENTER STUDY; SECRETION (PROCESS); TIME FACTOR; URINARY EXCRETION; URINE;

3-HYDROXYBUTYRIC ACID; ALGORITHMS; BENZHYDRYL COMPOUNDS; C-REACTIVE PROTEIN; CARBOHYDRATE METABOLISM; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLUCOSIDES; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; LIPOLYSIS; MEMBRANE TRANSPORT MODULATORS; RENAL ELIMINATION; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS;

EID: 84964608804     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1356     Document Type: Article

References (19)

1. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515
2. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012;8:495-502
3. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508
4. Gastaldelli A, Casolaro A, Ciociaro D, et al. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2009;297:E225-E230
5. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980;33:27-39
6. Mari A, Stojanovska L, Proietto J, Thorburn AW. A circulatory model for calculating non-steady-state glucose fluxes. Validation and comparison with compartmental models. Comput Methods Programs Biomed 2003;71:269-281
7. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988;37:287-301
8. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002;283:E1159-E1166
9. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 1984;74:2296-2299
10. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-517
11. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-1747
12. Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000;49:1367-1373
13. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
14. Munro JF, Campbell IW, McCuish AC, Duncan LJP. Euglycaemic diabetic ketoacidosis. BMJ 1973;2:578-580
15. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693
16. FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available from http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf. Accessed 22 June 2015
17. European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started. Risk of diabetic ketoacidosis to be examined. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/SGLT2-inhibitors-20/Procedure-started/WC500187926.pdf. Accessed 22 June 2015
18. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1730-1735
19. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-1642